Candel Therapeutics, Inc. $CADL
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS5
PHASE 3 / 2-32
RECRUITING2
READOUTS ≤12 MONTHS1
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| PrTK03 NCT01436968 |
P3 | Active, not recruiting | Prostate Cancer | 711 | 2024-08 (+107 mo) |
| aglatimagene besadenovec NCT02768363 |
P2 | Active, not recruiting | Prostate Cancer | 187 | 2024-11 (+83 mo) |
| Aglatimagene besadenovec NCT04495153 |
P2 | Active, not recruiting | Non Small Cell Lung Cancer | 90 | 2024-12-31 (+31 mo) |
| aglatimagene besadenovec + valacyclovir NCT07332000 |
P2 | Recruiting | Prostate Cancer Patients Treated by Radiotherapy; Prostate Cancer (Adenocarcinoma) | 45 | 2027-02 |
| LuTK03 NCT07660094 |
P3 | Recruiting | Non-squamous, Non-Small Cell Lung Cancer | 500 | 2031-10-22 |